GoldenGolden
RA Capital Management

RA Capital Management

A venture capital and private equity firm investing in public and private healthcare and life science companies.

RA Capital Management is a venture capital and private equity firm investing in public and private healthcare and life science companies that is headquartered in Boston, Massachusetts and was founded in 2004 by Richard Aldrich.

Investments

As of December 2019, RA Capital Management has made 114 investments, lead 28 investments, and made a total of 62 exits. Notable investments made by Ra Capital Management (as of December 2019) include: Audentes Therapeutics, 89bio, Bluebird Bio, Precision BioSciences, Moderna Therapeutics, Peloton Therapeutics, Orchard Therapeutics, Phathom Pharmaceuticals, Global Blood Therapeutics, and AveXis.

Investment funds
RA Capital Nexus Fund

On July 15, 2019 RA Capital Management announced raising $308 million for their RA Capital Nexus Fund. The fund increases the firms deal capiacity to $1 billion, and the total managed assets to about $2.5 billion. The firms plans on using the fund to invest in companies working on products and services realted to neurology, oncology, cardiovascular disease, and rare diseases.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Moderna Therapeutics

A biotechnology startup company that develops messenger RNA based therapeutics to treat diseases.

A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

Synthetic biology company that created novel DNA base pairs and uses them to incorporate novel amino acids into proteins for potential therapeutics in areas of cancer and autoimmune disorders.

Freenome is a San Francisco-based company which uses genetic analysis for early cancer detection and risk assessment.

T2 Biosystems is a Lexington, Massachusetts-based company developing diagnostic products targeting sepsis and in vitro diagnostic products intended to target sepsis, hemostasis, bacteria, and lyme disease founded in 2006 by Robin Toft.

Now known as Sierra Oncology, is a clinical stage drug development company in Vancouver that focuses on cancer and hematology treatments.

Nkarta Therapeutics is a biotechnology company using natural killer (NK) immune cells for cellular therapies.

A biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases.

A biopharmaceutical company developing chemoproteomics for drug discovery.

Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company focused on solving Duchenne muscular dystrophy.

Vor BioPharma is a biotechnology company developing hematopoietic stem cell therapy treatments for cancer.

Dimension Therapeutics is a biotechnology company that uses gene therapy to treat liver diseases.

Immunotherapy company focused on autoimmune diseases and cancer

A Forma Therapeutics is a bio-pharmaceutical company that focuses on therapeutics for rare hematological diseases and cancer.

Akouos is a Brookline, Massachusetts-based biotechnology company developing precision genetics-based medicines founded in 2016 by Emmanuel Simons.

Orchard Therapeutics is a biotechnology company developing gene therapies for rare diseases.

Seres Health is a Cambridge, Massachusetts-based company founded by David Berry.

Prevail Therapeutics is a New York City-based biotechnology company and a wholly owned subsidiary of Eli Lilly and Company.

55 Results
Results per page:
Page 1 of 3

People

Name
Role
LinkedIn

Andrew Levin, MD, PhD

Managing Director

Ben Dake, PhD

Venture Associate

Chieze Ibeneche-Nnewihe, PhD

Venture Associate

Derek DiRocco, PhD

Principal

Jake Simson, PhD

Principal

Jamie Kasuboski, PhD

Venture Senior Associate

Josh Resnick, MD

Managing Director

Mary Pat Connolly

Investment Research Coordinator

Matthew Hammond, PhD

Principal

Nathanial Brooks Horowitz

Corporate Development Manager

Neta Batscha

Analyst

Peter Kolchinsky, PhD

Managing Partner

Rajeev Shah

Managing Partner

Ryan Berry, PhD

Analyst

Zach Scheiner, PhD

Principal

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
April 15, 2021
BioSpace
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics - read this article along with other careers information, tips and advice on BioSpace
FinSMEs
April 8, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
FinSMEs
April 7, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
FinSMEs
April 7, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
FinSMEs
November 16, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Adagio Medical, Inc.
November 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Adagio Medical, Inc., un innovateur de premier plan pour le traitement de la fibrillation auriculaire (FA) et de la tachycardie ventriculaire...
Adagio Medical, Inc.
November 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Adagio Medical, Inc., ein führender Innovator für die Behandlung von Vorhofflimmern (AF) und ventrikulärer Tachykardie (VT) und Entwickler des...
Adagio Medical, Inc.
November 13, 2020
www.prnewswire.com:443
/PRNewswire/ -- Adagio Medical, Inc., un innovador líder para el tratamiento de la fibrilación atrial (FA) y taquicardia ventricular (TV), y desarrollador del...
Adagio Medical, Inc.
November 13, 2020
www.prnewswire.com:443
/PRNewswire/ -- Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the...
AlleyWatch
August 30, 2020
AlleyWatch
The Pulse of New York Tech
Jonathan Shieber
July 24, 2019
TechCrunch
One of the major problems that technology companies working to find a cure for cancer need to solve is finding a safe, minimally invasive way to detect cancers early. Almost all cancer screening will eventually require a biopsy, but determining whether that's necessary in the early stages of cancer can mean the difference between life [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.